Mineralys Therapeutics Inc.

About Mineralys Therapeutics Inc.

Mineralys Therapeutics is a company focused on improving outcomes for people managing hypertension, chronic kidney disease (CKD), and related cardio-renal-metabolic diseases driven by dysregulated aldosterone, through a targeted approach to control hypertension.

Products & Services

Lorundrostat:A product focused on addressing hypertension, likely through targeting aldosterone-related mechanisms.

Specialties

Hypertension control Aldosterone-related therapies Cardio-renal-metabolic diseases Chronic kidney disease (CKD)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 287500000 MR: - FA: approximately $287.5 million FAN: 287500000	D: 2025-09-04 FD: 2025-09-04	7 investors
2	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: $175.0 million FAN: 175000000	D: 2025-09-02 FD: 2025-09-02	7 investors
3	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: 250.0 million FAN: 250000000	D: 2025-09-02 FD: 2025-09-02	7 investors
4	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 201200000 MR: - FA: $201.2 million FAN: 201200000	D: 2025-03-18 FD: 2025-03-18	7 investors
5	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 175000000 MR: - FA: approximately $175.0 million FAN: 175000000	D: 2025-03-11 FD: 2025-03-11	7 investors
6	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2025-03-10 FD: 2025-03-10	7 investors
7	RT: Private Placement Financing (PIPE) T: - FT: Private Placement Financing (PIPE)	A: 120000000 MR: - FA: $120 million FAN: 120000000	D: 2024-02-08 FD: 2024-02-08	6 investors
8	RT: Initial Public Offering T: - FT: Initial Public Offering	A: 220800000 MR: - FA: $220.8 million FAN: 220800000	D: 2023-02-14 FD: 2023-02-14	6 investors
9	RT: IPO T: - FT: IPO	A: 192000000 MR: - FA: $192.0 million FAN: 192000000	D: 2023-02-09 FD: 2023-02-09	6 investors

Public Offering Latest

2025-09-04

$287.5M

7 investors (Pro only)

Public Offering 2025-09-02

$175.0M

Public Offering 2025-09-02

$250.0M

View 8 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jon Congleton

Chief Executive Officer

D

David Rodman

Chief Medical Officer

A

Adam Levy

Chief Financial Officer

E

Eric Warren

Chief Commercial Officer

J

Jessica Ibbitson

Executive Vice President, Operations

R

Robert McKean

Senior Vice President, CMC

View 22 more team members with Pro

Unlock Full Team Directory

Recent News